| Ocular Hypertension
Cosopt PF vs Vyzulta
Side-by-side clinical, coverage, and cost comparison for ocular hypertension.Deep comparison between: Cosopt Pf vs Vyzulta with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsVyzulta has a higher rate of injection site reactions vs Cosopt Pf based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Vyzulta but not Cosopt Pf, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Cosopt Pf
Vyzulta
At A Glance
Ophthalmic
Twice daily
Carbonic anhydrase inhibitor / beta-blocker
Topical ophthalmic
Once daily
Prostaglandin analog
Indications
- Glaucoma, Open-Angle
- Ocular Hypertension
- Glaucoma, Open-Angle
- Ocular Hypertension
Dosing
Glaucoma, Open-Angle, Ocular Hypertension One drop in the affected eye(s) twice daily; if other topical ophthalmic drugs are used, administer at least 5 minutes apart. Use the contents of each individual unit immediately after opening and discard any remaining solution.
Glaucoma, Open-Angle, Ocular Hypertension One drop in the conjunctival sac of the affected eye(s) once daily in the evening; do not administer more than once daily.
Contraindications
- Bronchial asthma or history of bronchial asthma, or severe chronic obstructive pulmonary disease
- Sinus bradycardia, second or third degree atrioventricular block, overt cardiac failure, or cardiogenic shock
- Hypersensitivity to any component of this product
—
Adverse Reactions
Most common (>=5%) Taste perversion (bitter, sour, or unusual taste), ocular burning and/or stinging (up to 30%), conjunctival hyperemia, blurred vision, superficial punctate keratitis, eye itching (5-15%)
Postmarketing Bradycardia, cardiac failure, cerebral vascular accident, chest pain, choroidal detachment following filtration surgery, depression, diarrhea, dry mouth, dyspnea, heart block, hypotension, iridocyclitis, myocardial infarction, nasal congestion, Stevens-Johnson syndrome, toxic epidermal necrolysis, paresthesia, photophobia, respiratory failure, skin rashes, urolithiasis, vomiting
Most common (>=2%) conjunctival hyperemia, eye irritation, eye pain, instillation site pain
Pharmacology
COSOPT PF combines dorzolamide hydrochloride (carbonic anhydrase II inhibitor) and timolol maleate (non-selective beta1/beta2-adrenergic receptor blocker); both components independently reduce elevated intraocular pressure by decreasing aqueous humor secretion, with additive IOP-lowering effect when combined.
Latanoprostene bunod is a prostaglandin analog and nitric oxide-donating agent that lowers intraocular pressure by increasing aqueous humor outflow through both the trabecular meshwork and uveoscleral routes.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Cosopt Pf
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (9/12)
Vyzulta
- Covered on 5 commercial plans
- PA (6/12) · Step Therapy (5/12) · Qty limit (9/12)
UnitedHealthcare
Cosopt Pf
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Vyzulta
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Cosopt Pf
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (2/3) · Qty limit (2/3)
Vyzulta
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Cosopt Pf.
No savings programs available for Vyzulta.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
Cosopt PfView full Cosopt Pf profile
VyzultaView full Vyzulta profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.